Moleculin Biotech, Inc. announced promising results from their Phase 1B/2 trial of Annamycin for treating soft tissue sarcoma lung metastases, showing a robust clinical benefit rate of 59.4% among ...

Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer Treatment with Annamycin results in statistically significant ...

Moleculin Biotech has announced encouraging topline efficacy outcomes from its US Phase IB/II trial, MB-107, of Annamycin for soft tissue sarcoma lung metastases (STS lung mets) treatment. The Phase ...

Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and Progression Free Survival (“PFS”) Clinical Benefit Rate (“CBR”) was 59.4% (n=32), comprised of ...

Oncology advancements focus on precision medicine, liquid biopsies, and novel therapies to improve outcomes and address care disparities. Value-based care models prioritize patient-centered approaches ...

Peroxisome proliferator-activated receptor gamma (PPARγ) mediates cell cycle arrest and adipocyte differentiation; has tumor suppressor activity in liposarcoma, lung, and prostate cancers; and ...

Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

HOUSTON, Sept. 23, 2024 /PRNewswire/ --Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates ...